QuantuMDx Wins UK Funding for Rapid Cancer Dx Tech | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuantuMDx and its university partners will use funding from the UK's Biomedical Catalyst program to develop and integrate the company's lab-on-a-chip technology into a device for rapidly diagnosing and staging cancers.

The company said on Sunday that it and its partners at the University of Newcastle and the University of Sheffield will use the £1.4 million ($2.2 million) in new funding to support development of a low-cost, sample-to-result benchtop device through an effort called the Q-Cancer project.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.